An additional advantage of a BsAb is that a second binding arm directed to a tumor-specific antigen may facilitate preferential targeting of the LGR5+ stem-cell-like cell within a tumor rather than an LGR5+ ISC. The gene discussed is LGR5; the disease is neoplasm.